Company Profile
Alvotech Stock Price, News & Catalysts
- Ticker:
- ALVO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Iceland
Stock performance
5.62 USD (-3.10%)
Close
Last updated: October 1, 2026
936M USD
Market cap
Why the stock is moving
The latest monitored company update is “Matvæla- og lyfjastofnun Bandaríkjanna (FDA) veitir viðbótarleyfi fyrir framleiðslu á hliðstæðunni við Humira í báðum framleiðslueiningum lyfjaverksmiðju Alvotech í Reykjavík.” The corresponding closing-price reaction is not yet available.
Company overview
Global Biosimilar Developer and Manufacturer
Alvotech is a biotechnology company focused exclusively on developing and manufacturing biosimilar medicines. It operates an integrated model covering cell-line development, process development, clinical studies, regulatory submissions, commercial-scale manufacturing, and supply to regional marketing partners.
Commercial Biosimilar Portfolio
The marketed portfolio includes biosimilars referencing Humira and Stelara, providing exposure to large immunology markets. Additional products referencing Prolia/Xgeva, Simponi/Simponi Aria, and Eylea broaden the portfolio into bone disease and ophthalmology.
Global Partnership Model
Alvotech generally partners with regional pharmaceutical companies for commercialization while retaining responsibility for development and manufacturing. This structure gives the company access to many markets without building a fully owned sales organization in every country.
Manufacturing-Centered Strategy
Complex biologic manufacturing is a core competitive capability. Alvotech's facilities support development through commercial supply, and regulatory inspections, manufacturing readiness, and reliable scale-up are critical to both product approvals and partner launches.
Expanding Late-Stage Pipeline
The pipeline includes AVT03, AVT05, AVT06, AVT16, AVT80, and additional biosimilars targeting high-value biologics across immunology, ophthalmology, oncology, and other specialty markets. Multiple candidates are being reviewed across the United States, Europe, and additional international jurisdictions.
Future catalysts
- FDA regulatory decisions in the fourth quarter of 2026 for resubmitted applications covering AVT03, AVT05, and AVT06.
- Regulatory decisions for additional late-stage biosimilars AVT16 and AVT80 following ongoing U.S. and European reviews.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Alvotech (ALVO)?
Alvotech (ALVO) most recently closed at 5.62 USD, a -3.10% move versus the previous session.
What is the market cap of Alvotech (ALVO)?
Alvotech currently has a market capitalization of 936M USD on BioPharmSignal.
What does Alvotech do?
Global Biosimilar Developer and Manufacturer Alvotech is a biotechnology company focused exclusively on developing and manufacturing biosimilar medicines. It operates an integrated model covering cell-line development, process development, clinical studies, regulatory submissions, commercial-scale manufacturing, and supply to regional marketing...
On which exchange is ALVO stock listed?
Alvotech (ALVO) is associated with NASDAQ, Iceland, Biopharma.
What is Global?
Global Biosimilar Developer and Manufacturer Alvotech is a biotechnology company focused exclusively on developing and manufacturing biosimilar medicines.
Which conditions is Alvotech targeting with Global?
Alvotech is associated with oncology, immunology, ophthalmology based on its company overview and current catalyst commentary.
How does Alvotech describe recent progress with Global?
FDA regulatory decisions in the fourth quarter of 2026 for resubmitted applications covering AVT03, AVT05, and AVT06. Regulatory decisions for additional late-stage biosimilars AVT16 and AVT80 following ongoing U.S. and European reviews.
What is Biosimilar?
Global Biosimilar Developer and Manufacturer Alvotech is a biotechnology company focused exclusively on developing and manufacturing biosimilar medicines.